FDA Fast-Track Program May Harm Patient Safety, Study Says
The U.S. Food and Drug Administration's decision to fast-track drugs made by AstraZeneca PLC, Novartis Pharmaceuticals Corp. and Boehringer Ingelheim GmbH for approval may have unduly risked patients' safety, according to...To view the full article, register now.
Already a subscriber? Click here to view full article